Overview

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.
Details
Lead Sponsor:
Bayer
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination